For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

≈ 50% of patients with metastatic melanoma have an oncogenic BRAF V600 mutation1

Metastatic melanoma patients with oncogenic BRAF V600 mutation statistic

BRAF V600 mutations result in constitutive activation of the MAPK pathway, which promotes cell growth and proliferation1

BRAF V600 mutations constitutive activation of the mitogen-activated protein kinase (MAPK) pathway

BRAF mutational testing should be mandatory in patients with advanced disease2 as stated by the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Cutaneous Melanoma

Patients with BRAF V600–mutant metastatic melanoma may have more aggressive disease than BRAF wild-type patients3,4

OS From Diagnosis of Metastatic Melanoma
According to BRAF Mutation Status
(total cohort, N = 197)3

BRAF metastatic melanoma overall survival

 

Long GV, et al. J Clin Oncol. 2011;29(10):1239-1246. Reprinted with permission. © 2011 American Society of Clinical Oncology. All rights reserved.

 

  • Patients with BRAF V600–mutant melanoma not treated with targeted therapy had worse survival outcomes vs patients with BRAF wild-type melanoma3
    • Patients with BRAF V600–mutant melanoma who received targeted therapy had similar survival outcomes vs patients without the BRAF mutation3
  • Patients with BRAF V600–mutant melanoma tended to have high-risk characteristics, such as an early onset of disease and presence of mitoses3

ERK, extracellular signal–regulated kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; OS, overall survival; WT, wild type.

References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 2. Dummer R, Hauschild A, Lindenblatt N, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v126-v132. 3. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239-1246. 4. Hugdahl E, Kalvenes MB, Puntervoll HE, Ladstein RG, Akslen LA. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. Br J Cancer. 2016;114(7):801-808.